Crossmark

T cells engineered against Dickkopf-1-A2 complex can be used to treat HLA-A2+ solid and hematologic cancers

Published Online: 2026-02-16

Authors

Zhang, Yufei https://orcid.org/0000-0002-0586-4073
Xiong, Wei

Qian, Jianfei

Duan, Rui

Guo, Qi

Wang, Qiang https://orcid.org/0000-0002-6141-0068
Wu, Wei

Zhang, Chuanchao

Li, Yabo https://orcid.org/0000-0003-3515-0140
Xian, Miao https://orcid.org/0009-0007-6001-1077
Lu, Yong https://orcid.org/0000-0003-0077-0040
Esnaola, Nestor F.

Chang, Jenny C.

Xiao, Liuling

Zhong, Ling

Yi, Qing https://orcid.org/0000-0003-1529-3398
License Information

Text and Data Mining valid from 2026-02-16

Accepted Manuscript valid from 2026-02-16
More Information

Article History

Received: 22 April 2025

Accepted: 4 February 2026

First Online: 16 February 2026

Competing interests

: J.Q., W.X., and Q.Y. are inventors on patents in the field of DKK1-A2 targeted Therapies. The remaining authors declare no competing financial interests.

Document is current